Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Andreas Stensvold"'
Autor:
Trond Velde Bogsrud, Ola Engelsen, Thuy Thu Thi Lu, Andreas Stensvold, Derek R. Johnson, Brian J. Burkett, Ayse Tuba Kendi, Mukesh K. Pandey, Rune Sundset, Jolanta M. Durski
Publikováno v:
EJNMMI Research, Vol 14, Iss 1, Pp 1-6 (2024)
Abstract Background The main objective is to discuss why treatment of non-prostate cancers with [177Lu]Lu-PSMA-radioligand achieved only low tumor dose in most published cases, despite high uptake on PSMA PET. We use a patient with renal cell carcino
Externí odkaz:
https://doaj.org/article/c7a558f85543439ab71692c0bdc3c94e
Publikováno v:
Acta Oncologica, Vol 63, Iss 1 (2024)
Background: A significant proportion of patients with incurable cancer receive systemic anticancer therapy (SACT) within their last 30 days of life (DOL). The treatment has questionable benefit, nevertheless is considered a quality indicator of end-o
Externí odkaz:
https://doaj.org/article/5afb6ca21294466d88cbebb1b36b6d37
Autor:
Zygimantas Zaboras, Camilla Tøvik Jørgensen, Andreas Stensvold, Heidi Hassel Pettersen, Aleksandra Galovic Grdinic, Sigrid Kufaas Brækkan, Waleed Ghanima, Mazdak Tavoly
Publikováno v:
TH Open, Vol 08, Iss 01, Pp e132-e140 (2024)
Background International guidelines are increasingly recommending direct oral anticoagulants (DOACs) as the first-line treatment for cancer-associated thrombosis (CAT). However, data regarding treatment patterns and adherence to guidelines in patient
Externí odkaz:
https://doaj.org/article/08a03115bfdf4041b564839d425f1229
Autor:
Åslaug Helland, Hege G. Russnes, Gro Live Fagereng, Khalid Al-Shibli, Yvonne Andersson, Thomas Berg, Line Bjørge, Egil Blix, Bodil Bjerkehagen, Sigmund Brabrand, Marte Grønlie Cameron, Astrid Dalhaug, Dalia Dietzel, Tom Dønnem, Espen Enerly, Åsmund Flobak, Sverre Fluge, Bjørnar Gilje, Bjørn Tore Gjertsen, Bjørn Henning Grønberg, Kari Grønås, Tormod Guren, Hanne Hamre, Åse Haug, Daniel Heinrich, Geir Olav Hjortland, Eivind Hovig, Randi Hovland, Ann-Charlotte Iversen, Emiel Janssen, Jon Amund Kyte, Hedda von der Lippe Gythfeldt, Ragnhild Lothe, Jo-Åsmund Lund, Leonardo Meza-Zepeda, Monica Cheng Munthe-Kaas, Olav Toai Duc Nguyen, Pitt Niehusmann, Hilde Katarina NilsenPuco, Anne Hansen Ree, Tonje Bøyum Riste, Karin Semb, Eli Sihn Samdal Steinskog, Andreas Stensvold, Pål Suhrke, Øyvind Tennøe, Geir E. Tjønnfjord, Liv Jorunn Vassbotn, Eline Aas, Kristine Aasebø, Kjetil Tasken, Sigbjørn Smeland
Publikováno v:
Journal of Translational Medicine, Vol 20, Iss 1, Pp 1-11 (2022)
Abstract Background Matching treatment based on tumour molecular characteristics has revolutionized the treatment of some cancers and has given hope to many patients. Although personalized cancer care is an old concept, renewed attention has arisen d
Externí odkaz:
https://doaj.org/article/bc8aeb65ca3b4815a6a4cb94d009f0a6
Autor:
Ann-Chatrin Linqvist Leonardsen, Ann Karin Helgesen, Andreas Stensvold, Jannik Magnussen, Vigdis A. Grøndahl
Publikováno v:
BMC Health Services Research, Vol 22, Iss 1, Pp 1-9 (2022)
Abstract Background The COVID-19 pandemic triggered an unprecedented demand for digital health technology solutions, such as remote monitoring. Previous research has focused on patients with chronic diseases, and their experiences with remote monitor
Externí odkaz:
https://doaj.org/article/84820164434b4015965eddc1c6467336
Autor:
Åslaug Helland, Hege G. Russnes, Gro Live Fagereng, Khalid Al-Shibli, Yvonne Andersson, Thomas Berg, Line Bjørge, Egil Blix, Bodil Bjerkehagen, Sigmund Brabrand, Marte Grønlie Cameron, Astrid Dalhaug, Dalia Dietzel, Tom Dønnem, Espen Enerly, Åsmund Flobak, Sverre Fluge, Bjørnar Gilje, Bjørn Tore Gjertsen, Bjørn Henning Grønberg, Kari Grønås, Tormod Guren, Hanne Hamre, Åse Haug, Daniel Heinrich, Geir Olav Hjortland, Eivind Hovig, Randi Hovland, Ann-Charlotte Iversen, Emiel Janssen, Jon Amund Kyte, Hedda von der Lippe Gythfeldt, Ragnhild Lothe, Jo-Åsmund Lund, Leonardo Meza-Zepeda, Monica Cheng Munthe-Kaas, Olav Toai Duc Nguyen, Pitt Niehusmann, Hilde Nilsen, Katarina Puco, Anne Hansen Ree, Tonje Bøyum Riste, Karin Semb, Eli Sihn Samdal Steinskog, Andreas Stensvold, Pål Suhrke, Øyvind Tennøe, Geir E. Tjønnfjord, Liv Jorunn Vassbotn, Eline Aas, Kristine Aasebø, Kjetil Tasken, Sigbjørn Smeland
Publikováno v:
Journal of Translational Medicine, Vol 20, Iss 1, Pp 1-2 (2022)
Externí odkaz:
https://doaj.org/article/d1675781ce0d4327ba7f57f4b202f48a
Autor:
Trygve Lofterød, Elin S. Mortensen, Hawa Nalwoga, Tom Wilsgaard, Hanne Frydenberg, Terje Risberg, Anne Elise Eggen, Anne McTiernan, Sura Aziz, Erik A. Wist, Andreas Stensvold, Jon B. Reitan, Lars A. Akslen, Inger Thune
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-11 (2018)
Abstract Background High triglycerides and low levels of high density lipoprotein (HDL)-cholesterol are observed to promote tumor growth. However, whether breast cancer heterogeneity may explain the contradictory influence of triglycerides and choles
Externí odkaz:
https://doaj.org/article/76f1e9d55e5641e5a4e31b1716510d28
Autor:
Johan Bjerner, Ola Bratt, Kirsti Aas, Peter C. Albertsen, Sophie D. Fosså, Rune Kvåle, Hans Lilja, Christoph Müller, Stig Müller, Andreas Stensvold, Owen Thomas, Oluf D. Røe, Andrew Vickers, Jochen Walz, Sigrid V. Carlsson, Jan Oldenburg
Publikováno v:
European Urology.
Autor:
Wolfgang Lilleby, Andreas Stensvold, Theodore L. DeWeese, Phuoc T. Tran, Matthew P. Deek, Therese Seierstad, Victoria Vaage, Knut Håkon Hole
Publikováno v:
The Prostate. 80:1322-1327
Background Dose escalated radiation therapy (RT) combined with long-term androgen deprivation therapy (ADT) is a standard of care option for men with high-risk and locally advanced prostate cancer (PCa). However, the optimal dose of escalated RT and
Autor:
Kari V. Monsen, Sophie D. Fosså, Tor Å. Myklebust, Sigbjørn Smeland, Alv A. Dahl, Andreas Stensvold
Publikováno v:
Acta oncologica (Stockholm, Sweden). 61(3)
In a cross-sectional observational study to explore long-term satisfaction with treatment among men who had undergone radical prostatectomy (RP) or definitive pelvic radiotherapy (RT) for prostate cancer (PCa).After mean 7 years from therapy (range: